Anuh Pharma Limited (ANUHPHR)

Loading page…

Anuh Pharma Limited (ANUHPHR) · mywealthgrid

About

Small-cap pharmaceutical manufacturer with ₹763.62 Cr market cap and quarterly revenue ₹186–202 Cr (up from ₹97 Cr in Mar 2021). Debt-free with consistent profitability; promoter holds 71.8% and institutional participation is minimal (FII 0.01%, DII 0%).

Face value: ₹5

Market cap

₹860 Cr

P/E

19.5×

P/B

2.4×

Dividend yield

3.5%

ROE

12.1%

ROCE

16%

Debt / equity

OPM

EPS (TTM)

₹4.4

Book value

₹35.1

52-week high

—

52-week low

—

Key insights

Company research notes and source-linked reviews

Key risks

Operating margin volatile: 5.52% (Jun 2025) to 9.84% (Mar 2026), with quarterly profit swinging ₹7.61–13.45 Cr—verify what drives this inconsistency.
Stock fell 15.74% over 1 year despite consistent profits; EPS ranged ₹0.76–2.49 quarterly, suggesting valuation or execution concerns—verify the cause.
Minimal institutional ownership (FII 0.01%, DII 0%) and thin public float (28.19%) may constrain analyst coverage and liquidity.
Pharma sector risks—pricing regulation, generic competition, input costs, supply-chain resilience—should be verified against the company's therapeutic areas, sourcing, and competitive position.

Generated analysis · source review pending

Growth drivers

Revenue scaled from ₹97 Cr (Mar 2021) to ₹194–202 Cr (recent quarters); verify what segments, products, or geographies drove this and whether the pace can sustain.
Operating margin improved from 4.19% (Mar 2021) to 9.84% (Mar 2026)—verify whether scale, product mix, efficiency, or other factors drove this and its durability given recent volatility.
Quarterly net profit volatility (₹7.61–13.45 Cr) hints at seasonality or business cycles; stabilising this would improve earnings predictability and valuation appeal.

Generated analysis · source review pending

2,177 historical price candles were omitted because the exchange source has not been verified.

₹86.9-3.1%1Y

Quick read

rule-based

Pros

+High return on capital employed of 21.7%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 116.4×
+Dividend yield of 3.5%
+Dividend payout of 68.1% of profit
+High promoter holding of 71.8% with no pledge

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

58/100

Business quality: 55
Growth: 50
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	324	204	241	321	307	432	487	527	647	662	772
COGS	-254	-150	-182	-243	-230	330	378	401	487	499	600
Gross profit	—	—	—	—	—	102	109	126	160	162	172
	544	335	404	534	514	58	62	75	85	101	110
	34	20	19	30	23	45	47	51	75	61	62
OPM %	10.5%	9.7%	7.8%	9.2%	7.4%	10.3%	9.6%	9.7%	11.6%	9.2%	8%
Depreciation	—	—	—	2	7	15	12	10	9	9	11
Interest	0	0	0	0	1	1	1	0	0	1	0
	2	5	8	5	4	11	5	6	12	9	4
Profit before tax	38	25	26	32	19	39	39	47	78	61	54
Tax	12	8	7	9	5	10	9	11	18	14	13
Tax %	32%	30%	26.9%	27.9%	25.3%	26.3%	21.9%	23.8%	23.3%	22.4%	24.3%
	26	18	19	23	14	28	31	36	60	47	41
PAT margin %	8%	8.6%	7.8%	7.3%	4.7%	6.6%	6.3%	6.9%	9.3%	7.2%	5.3%
EPS (₹)	16.7	7	7.8	9.3	5.7	9	—	—	12	9.5	4.1
EPS adjusted (₹)	—	—	—	—	—	2.8	3.1	3.6	6	4.7	4.1
	15%	35.7%	35.4%	29.5%	48.2%	16.7%	—	—	20.9%	15.9%	36.6%
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	25	25	25	25	25	50
Reserves	166	189	216	266	301	302
	14	3	0	2	11	0
	128	130	164	152	170	205
Total equity & liabilities	333	347	405	446	507	557
	71	60	52	48	58	57
CWIP	0	0	0	0	0	0
Investments	31	43	91	97	106	84
	230	244	262	300	342	416
Total assets	333	347	405	446	507	557

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	23.7%	22.4%	23.9%	24.8%	24.5%	22.3%
EBITDA margin %	9.2%	7.4%	10.3%	9.6%	9.7%	11.6%	9.2%	8%
EBIT margin %	8.7%	5.1%	6.8%	7.2%	7.9%	10.3%	7.9%	6.5%
PAT margin %	7.3%	4.7%	6.6%	6.3%	6.9%	9.3%	7.2%	5.3%
Working capital
Receivable days	—	—	90	102	118	107	119	113
Inventory days	—	—	90	77	66	57	54	90
Payable days	—	—	133	117	139	105	115	114
NWC days	—	—	48	62	46	58	59	89
Leverage
Current ratio	—	—	1.7	1.98	1.91	2.2	2.11	2.22
Debt to EBITDA	—	—	0.31	0.07	0	0.03	0.17	0
Debt to equity	—	—	0.07	0.01	0	0.01	0.03	0
Interest coverage	191.6	25.3	26.9	41.8	216.8	224.7	99.4	116.4
Asset turnover	—	—	1.3	1.4	1.3	1.45	1.31	1.38
Return ratios
Return on assets %	—	—	8.5%	8.8%	8.9%	13.5%	9.3%	7.4%
Return on capital employed %	—	—	20.7%	19.6%	20.7%	29.3%	19.8%	16%
Return on equity %	—	—	14.9%	14.3%	15%	20.6%	14.5%	11.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	70.59%	69.94%	69.92%	69.8%	69.92%	69.92%	69.92%	69.92%	71.82%	71.82%	71.8%	71.8%
	0%	0%	0.03%	0.03%	0.02%	0.02%	0.04%	0.04%	0%	0%	0.05%	0.01%
DII	0%	0%	0.11%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	29.41%	30.06%	29.94%	30.17%	30.06%	30.06%	30.04%	30.04%	28.18%	28.18%	28.15%	28.19%
No. of shareholders	—	—	—	—	—	—	—	—	28,250	27,889	27,425	27,484

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

of the company's equity

All mutual funds

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	770	0.01	0.01%	0.001%	+1

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Intimation of Reaffirmation of Credit Ratings by ICRA Credit Rating Limited under Regulation 30 of SEBI (LODR) Regulations, 2015.16 Sept 2025 from ICRA

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

18 announcementsExport CSV

7 Aug 2026, 6:51 pmCompany Update

Announcement Under Regulation 30 (LODR) - Adoption Of Revised Policy Of Related Party Transactions,

General PDF

7 Aug 2026, 6:43 pmCompany Update

Announcement Under Regulation 30 (LODR) - Intimation Regarding The Request Received For Withdrawal Of Application For Reclassification.

General PDF

7 Aug 2026, 6:32 pmResult

Results - Financial Results For June 30, 2026

Financial Results PDF

7 Aug 2026, 5:51 pmBoard Meeting

Board Meeting Outcome For The Board Meeting Held On 07/08/2026

Outcome of Board Meeting PDF

3 Aug 2026, 4:42 pmBoard Meeting

Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ended 30Th June, 2026.

Exchange filing PDF

18 Jul 2026, 5:08 pmCompany Update

General Updates

General PDF

18 Jul 2026, 4:51 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

18 Jul 2026, 4:33 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

Date	Category	Subject	Filing
7 Aug 2026, 6:51 pm	Company Update General	Announcement Under Regulation 30 (LODR) - Adoption Of Revised Policy Of Related Party Transactions,	PDF
7 Aug 2026, 6:43 pm	Company Update General	Announcement Under Regulation 30 (LODR) - Intimation Regarding The Request Received For Withdrawal Of Application For Reclassification.

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	23.7%	22.4%	23.9%	24.8%	24.5%	22.3%
EBITDA margin %	9.2%	7.4%	10.3%	9.6%	9.7%	11.6%	9.2%	8%
EBIT margin %	8.7%	5.1%	6.8%	7.2%	7.9%	10.3%	7.9%	6.5%
PAT margin %	7.3%	4.7%	6.6%	6.3%	6.9%	9.3%	7.2%	5.3%
Working capital
Receivable days	—	—	90	102	118	107	119	113
Inventory days	—	—	90	77	66	57	54	90
Payable days	—	—	133	117	139	105	115	114
NWC days	—	—	48	62	46	58	59	89
Leverage
Current ratio	—	—	1.7	1.98	1.91	2.2	2.11	2.22
Debt to EBITDA	—	—	0.31	0.07	0	0.03	0.17	0
Debt to equity	—	—	0.07	0.01	0	0.01	0.03	0
Interest coverage	191.6	25.3	26.9	41.8	216.8	224.7	99.4	116.4
Asset turnover	—	—	1.3	1.4	1.3	1.45	1.31	1.38
Return ratios
Return on assets %	—	—	8.5%	8.8%	8.9%	13.5%	9.3%	7.4%
Return on capital employed %	—	—	20.7%	19.6%	20.7%	29.3%	19.8%	16%
Return on equity %	—	—	14.9%	14.3%	15%	20.6%	14.5%	11.7%

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-19	29	54	13	37	-3
	52	-8	-43	1	-20	18
	-33	-19	-12	-9	-5	-26
Net cash flow	0	2	-2	5	12	-12
Free cash flow	-25	27	52	8	17	-11
CFO / Operating profit %	-42%	61.6%	105.1%	17.2%	60.9%	-4.9%

Anuh Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Events

Announcements

Not in the F&O segment

22

1

4

Announcements

Annual reports

Credit ratings

Compounded sales growth

Compounded profit growth

Return on equity

Anuh Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Events

Announcements

Ratio timeline

Not in the F&O segment

Quarterly record

Dividends22

Board meetings1

Bonus issues4

Board and management

Announcements

Annual reports

Credit ratings

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

22

1

4